The Structure Behind Clinical Trials
Clinical trials follow a clearly defined sequence designed to protect participants while generating reliable scientific data. Before a trial begins, researchers must submit a detailed protocol — a plan describing the study's objectives, design, eligibility criteria, and safety procedures — for review by an Institutional Review Board (IRB). The IRB is an independent committee that evaluates whether the proposed research is ethically sound and adequately protects participants.
Once approved, a trial typically advances through four phases:
- Phase I: A small group of participants receives the treatment to assess safety and determine safe dosage ranges.
- Phase II: A larger group tests whether the treatment shows signs of effectiveness while researchers continue monitoring side effects.
- Phase III: The treatment is compared against current standard care in a much larger population, often across multiple medical centers.
- Phase IV: Post-approval monitoring continues to gather long-term data on safety and outcomes in the general population.
Each phase must demonstrate sufficient evidence before advancing to the next. This layered approach reflects the scientific and ethical commitment to ensuring that no treatment reaches widespread use without thorough evaluation.
4
Phases required before broad treatment approval
The U.S. Food and Drug Administration requires evidence from all four phases before a new drug or treatment can be approved for general use.
~460,000
Clinical trials registered globally
According to the ClinicalTrials.gov registry maintained by the U.S. National Institutes of Health, hundreds of thousands of trials are listed across conditions and countries.
< 10%
Cancer patients who participate in clinical trials
Research has consistently found that a small minority of eligible cancer patients enroll in trials, highlighting awareness and access gaps in the system.
What Informed Consent Actually Means
Before enrolling in any clinical trial, participants go through an informed consent process. This is not simply signing a form — it is an ongoing conversation between the research team and the patient. Researchers are required to explain the purpose of the trial, what participation involves, potential risks and benefits, available alternatives, and the participant's right to withdraw at any time without affecting their standard care.
Informed consent documentation can be lengthy and technical. Patients are encouraged to ask questions, involve family members, and take time to review all materials before making a decision. If anything is unclear, asking for clarification is not just acceptable — it is expected.
Prepare Questions Before Meeting the Research Team
When meeting with a clinical trial coordinator or investigator, bring a written list of questions about the treatment, schedule, costs, and your rights as a participant. Ask specifically what happens to your care if the trial ends early or if you choose to withdraw. Feeling confident in your understanding before you sign anything is your right — and a good sign of a well-run trial.
It's also worth noting that consent is not a one-time event. If new safety information emerges during a trial, researchers must update participants through a process called re-consent.
Why Some Patients Choose to Participate
The decision to enroll in a clinical trial is deeply personal. Motivations differ widely across individuals and diagnoses.
For some, especially those whose cancer has not responded to standard treatments, a trial may offer access to a therapy not yet broadly available. For others, the appeal lies in the close monitoring and care that often accompanies trial participation. A meaningful number of participants also express a desire to contribute to research that may benefit future patients — a factor that can carry significant personal weight.
At the same time, participation is not the right path for everyone. Trials require time commitments for visits and monitoring, and not all patients meet eligibility criteria. Geographic location can also limit access, though some trials now incorporate remote or hybrid components.
Before pursuing any trial, having an open conversation with your oncologist is essential. If you're looking for a framework to guide those discussions, questions worth asking your oncologist can help you prepare for an informed, productive appointment.
“Patients who participate in clinical trials not only have the chance to benefit from the latest research, but they also make it possible for the next generation of patients to receive better, more targeted treatments.”
— National Cancer Institute, U.S. federal agency for cancer research and public health information
This article is for informational purposes only and does not constitute medical advice. Speak with a qualified healthcare professional before making any decisions about your treatment or participation in research studies.
Frequently Asked Questions
Clinical trials have four phases. Phase I tests safety and dosage in a small group. Phase II evaluates effectiveness and side effects in a larger group. Phase III compares the new treatment to standard care across many patients. Phase IV monitors long-term outcomes after a treatment is approved.
Not necessarily. Some trials use a control group that receives standard treatment or, in some cases, a placebo. Participants are typically informed about the possibility of being assigned to a control group before enrolling. Researchers use this design to ensure results are scientifically valid.
All trials carry some level of risk, and unknown side effects are possible with experimental treatments. However, trials are designed with multiple safeguards including IRB oversight, informed consent, and ongoing safety monitoring. Independent review boards can pause or stop a trial if safety concerns arise.
Eligibility depends on specific criteria such as cancer type, stage, age, and prior treatments. Your oncologist is the best starting point. The ClinicalTrials.gov registry, maintained by the U.S. National Institutes of Health, also lists active trials and their eligibility requirements.
Costs vary. Trial sponsors often cover the investigational treatment and related testing. However, routine care costs may still fall to the patient or their insurance. It's important to discuss the financial aspects with the trial team and your insurance provider before enrolling.
The content on this site is for informational purposes only and is not a substitute for professional advice. Always consult a qualified professional for guidance specific to your situation.
